| Last Updated:
Creating DOI. Please wait...
The British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA) is a prospective cohort study of patients, recruited from rheumatology centres across Great Britain, who meet the CASPAR criteria for psoriatic arthritis and are either
(a) Commencing a biologic or other targeted disease-modifying anti-rheumatic drug (bDMARD or tsDMARD); or
(b) Naïve to all bDMARDs/tsDMARDs.
Clinical data are extracted from participants’ medical records, including symptom onset and diagnosis, joint, skin and nail symptoms and history, dactylitis and enthesitis. Physical measurements (height, weight and 66/68 joint counts) and a detailed drug history are taken. Participants are also asked to complete detailed questionnaires comprising instruments relating to general health and quality of life, axial disease, sleep and fatigue, impact of disease, functional status, mental health, other symptoms and occupational status.
Study duration is five years in the first instance, and all participants will be followed up annually until the end of the study. Participants commencing a bDMARD/tsDMARD are also followed up three and six months after the start of therapy. Disease activity, including C-reactive protein, is assessed at each visit; participants from some centres are invited to donate additional blood and urine samples to the study biobank at the time of commencing bDMARDs/tsDMARDs therapy, and at three-months.